Corcept's Experimental Drug Shows Promise in Extending Life for Ovarian Cancer Patients

Corcept Therapeutics' (CORT) relacorilant combined with chemotherapy reduced death risk by 35% in platinum-resistant ovarian cancer patients, with FDA decision expected July 2026.